New drug trial aims to tame severe eczema in kids
NCT ID NCT05388760
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe. Children received injections over several weeks and used moisturizers daily. The trial is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tralokinumab
What this could lead to
If successful, this could provide a new treatment option for children with moderate-to-severe eczema that is not well controlled by creams.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 28 children, so results may not apply to all. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LEO Pharma Investigational Site
Brno, 625 00, Czechia
-
LEO Pharma Investigational Site
Prague, 150 06, Czechia
-
LEO Pharma Investigational Site
Reims, Ardennes, 51100, France
-
LEO Pharma Investigational Site
Rotterdam, 3011 TG, Netherlands
-
LEO Pharma Investigational Site
Utrecht, 3584 CX, Netherlands
-
LEO Pharma Investigational Site
Cadiz, Andalusia, 11009, Spain
-
LEO Pharma Investigational Site
Esplugues de Llobregat, Barcelona, 08950, Spain
-
LEO Pharma Investigational Site
Alicante, 03010, Spain
-
LEO Pharma Investigational Site
Manchester, Greater Manchester, M13 9WL, United Kingdom
-
LEO Pharma Investigational Site
London, SE1 9RT, United Kingdom
-
LEO Pharma Investigational Site
Sheffield, S10 2TH, United Kingdom